Cava (CAVA) made its public debut on the New York Stock Exchange this past summer. Cava Co-Founder and CEO Brett Schulman sits down with Yahoo Finance's Brooke DiPalma at the Yahoo Finance Invest conference to discuss the company's growth since its IPO, how it is utilizing new technology, and the potential impact of weight loss drugs. Cava is focused “on the next ten years plus, not the next ten days. Stocks will go up and down. We're really excited with how the market received our offering and how it’s been received since,” Schulman assures, later adding: “We’re focused on really delivering that Mediterranean cuisine and doing it in communities across the country as we grow.” The Mediterranean fast-casual chain is leaning into digitalization for with its online sales, but is hesitant to adopt automation trends: “Our mission is to bring heart, health, and humanity to food and if it was all robots, I think we wouldn’t live up to that humanity piece. And we’ve always looked at technology to enhance the human experience, not replace it,” Schulman adds. Weight loss drugs, like Novo Nordisk's (NVO) Ozempic, are “recalibrating… diets to live a more healthful, balanced diet and lifestyle, which really lends itself to our cuisine,” Schulman says. “We think it could be a net benefit for us.” Click here to watch more from Yahoo Finance Invest.

Read more --->